JAMA CardiologyPeer-Reviewed Publication

JAMA Network

FacebookXLinkedInWeChatBlueskyMessageWhatsAppEmail

About The Study: The efficacy of finerenone was consistent regardless of atrial fibrillation status in this study. New-onset atrial fibrillation was associated with a substantially higher risk of subsequent outcomes.

Corresponding Author: To contact the corresponding author, John J. V. McMurray, MD, email john.mcmurray@glasgow.ac.uk.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamacardio.2025.0848)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.

#  #  #

Media advisory: This study is being presented at the American College of Cardiology’s Annual Scientific Session.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2025.0848?guestAccessKey=4d81e04e-ccb5-4549-bea3-a65bd04cb4c3&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=032925

---

Journal

JAMA Cardiology

https://meet.google.com/call?authuser=0&hl=en-GB&mc=KAIwAZoBFDoScGludG9fZTM0Z2Nqa2J1MmFiogE7GgIQADICUAA6AhABSgQIARABWgIIAGoCCAFyAggBegIIAogBAJIBAhABmgEEGAEgAKIBAhAA4gECCACyAQcYAyAAKgEwwgECIAHYAQE&origin=https%3A%2F%2Fmail.google.com&iilm=1743435682397